Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025
Journey Medical Corporation (NASDAQ: DERM), a commercial-stage pharmaceutical company focused on marketing FDA-approved dermatological treatments, has scheduled its first quarter 2025 financial results announcement for May 14, 2025, after U.S. market close.
The company will host a conference call and audio webcast at 4:30 p.m. ET on the same day. U.S. participants can dial 1-866-777-2509, while international callers should use 1-412-317-5413. The webcast will be accessible through Journey Medical's website and will remain available for approximately 30 days after the call.
Journey Medical Corporation (NASDAQ: DERM), un'azienda farmaceutica in fase commerciale specializzata nella commercializzazione di trattamenti dermatologici approvati dalla FDA, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per il 14 maggio 2025, dopo la chiusura del mercato statunitense.
La società terrà una conference call e una trasmissione audio in diretta alle 16:30 ET dello stesso giorno. I partecipanti negli Stati Uniti possono chiamare il numero 1-866-777-2509, mentre i chiamanti internazionali dovrebbero utilizzare il 1-412-317-5413. La trasmissione sarà accessibile tramite il sito web di Journey Medical e resterà disponibile per circa 30 giorni dopo la chiamata.
Journey Medical Corporation (NASDAQ: DERM), una empresa farmacéutica en etapa comercial centrada en la comercialización de tratamientos dermatológicos aprobados por la FDA, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el 14 de mayo de 2025, después del cierre del mercado estadounidense.
La compañía realizará una llamada en conferencia y una transmisión de audio por internet a las 4:30 p.m. ET ese mismo día. Los participantes en EE. UU. pueden marcar el 1-866-777-2509, mientras que los llamantes internacionales deben usar el 1-412-317-5413. La transmisión estará disponible a través del sitio web de Journey Medical y permanecerá accesible durante aproximadamente 30 días después de la llamada.
Journey Medical Corporation (NASDAQ: DERM)는 FDA 승인 피부과 치료제 마케팅에 주력하는 상업 단계의 제약 회사로, 2025년 1분기 재무 결과 발표를 2025년 5월 14일 미국 시장 마감 후에 예정하고 있습니다.
회사는 같은 날 오후 4시 30분 ET에 컨퍼런스 콜과 오디오 웹캐스트를 진행할 예정입니다. 미국 참가자는 1-866-777-2509로 전화할 수 있으며, 국제 참가자는 1-412-317-5413을 이용해야 합니다. 웹캐스트는 Journey Medical 웹사이트를 통해 접속 가능하며, 콜 이후 약 30일간 시청할 수 있습니다.
Journey Medical Corporation (NASDAQ : DERM), une société pharmaceutique en phase commerciale spécialisée dans la commercialisation de traitements dermatologiques approuvés par la FDA, a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le 14 mai 2025, après la clôture du marché américain.
La société organisera une conférence téléphonique et une diffusion audio en direct à 16h30 ET le même jour. Les participants américains peuvent composer le 1-866-777-2509, tandis que les appelants internationaux doivent utiliser le 1-412-317-5413. La diffusion sera accessible via le site web de Journey Medical et restera disponible environ 30 jours après l'appel.
Journey Medical Corporation (NASDAQ: DERM), ein pharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf die Vermarktung von von der FDA zugelassenen dermatologischen Behandlungen spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für den 14. Mai 2025, nach Börsenschluss in den USA, geplant.
Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz und eine Audio-Webcast veranstalten. Teilnehmer aus den USA können die Nummer 1-866-777-2509 wählen, internationale Anrufer sollten die 1-412-317-5413 nutzen. Der Webcast ist über die Website von Journey Medical zugänglich und bleibt etwa 30 Tage nach dem Anruf verfügbar.
- None.
- None.
Company to host conference call to discuss financial results and provide a corporate update on May 14, 2025 at 4:30 p.m. ET
SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2025 financial results after the U.S. financial markets close on Wednesday, May 14, 2025. Journey Medical management will conduct a conference call and audio webcast on Wednesday, May 14, 2025 at 4:30 p.m. ET.
To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the Journey Medical conference call. Participants can register for the conference by navigating to https://dpregister.com/sreg/10199519/ff117b0a70. Please note that registered participants will receive their dial-in number upon registration.
A live audio webcast can be accessed on the News and Events page of the Investors section of Journey Medical’s website, www.journeymedicalcorp.com, and will remain available for replay for approximately 30 days after the conference call.
About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets eight FDA-approved prescription drugs for dermatological conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com.
Company Contact:
Jaclyn Jaffe
Journey Medical Corporation
(781) 652-4500
ir@jmcderm.com
Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com
FAQ
When will Journey Medical (DERM) report Q1 2025 earnings?
How can I join Journey Medical's Q1 2025 earnings call?
Where can I access Journey Medical's Q1 2025 earnings webcast?
What is Journey Medical Corporation's main business focus?
